NMP-41 data

NMPS's colorectal cancer assay was shown to be more than twice as sensitive as carcinoembryonic antigen assay (CEA) in a study of 96 healthy donors and 56 colon cancer patients, according to data that will be presented this week at the American Association for Cancer Research meeting in Washington.

Initial results from the prototype assay indicated a 71 percent sensitivity (17/24 patients) in identifying early-stage cancer; NMPS' study showed that the FDA-approved CEA test was only 33 percent sensitive (8/24) in identifying the same patients with early-stage colorectal disease. ...